Everand Logo

Welcome to Everand!

  • STAT

    3 stories to watch in health tech in 2020

    Can health tech make real money? Who owns these data anyway? Will bias be battled? We take a crack at predicting the answers.
    by Casey Ross and Rebecca Robbins Dec 24, 2019 3 minutes

    Judging by the numbers, digital health companies had another huge year in 2019.

    Total investment in the sector was expected to reach a record $8.4 billion, as firms raked in cash to develop novel wearables, personalized digital services, and machine learning tools to improve treatment of debilitating diseases. Several companies also entered the public markets, and tech giants such as Apple (APPL), Amazon, Google, and Microsoft (MSFT) ramped up their health investments and recruitment of clinical leaders.  

    But much of that activity is fueled by hype and hope. Heading into

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
    Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

    Related Books & Audiobooks